Project Grant 2151477
Award Date
2/15/22
Completion Date
11/30/22
Dollars Obligated
$256K
Federal Agency
Division of Industrial Innovation
Awardee
Diant Pharma Inc. (KSC4E53LAX37)
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Storrs, CT 06269, USA
Similar Awards
Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...
Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...
Infinifluidics Inc. received a $256,000 National Science Foundation Project Grant under the Engineering (47.041) federal grant program. The grant supports development of on-demand continuous and sterile manufacturing of injectable drug delivery systems at industrial scale on a portable microfluidic chip from July 1, 2021 to June 30, 2022. The Engineering program seeks to improve quality of life and economic strength through innovative engineering research and education. This award will allow...
This $274,990 National Science Foundation (NSF) SBIR Phase I Project Grant under the Technology, Innovation, and Partnerships (CFDA 47.084) program was awarded to Eascra Biotech, Inc., a for-profit small business based in Pawtucket, Rhode Island. The project aims to advance the regulatory pathway for commercializing space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for effectively treating solid tumors. The key objectives are to demonstrate the comparability of...
Nanored LLC received a $246,731 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the development of a novel SARS-CoV-2 virus-like particle optimized to deliver shRNA therapeutics from March 1, 2021 through April 30, 2022. The grant aims to prevent and treat COVID-19 infection through a delivery method utilizing virus-like particles to transport self-amplifying short hairpin RNA molecules into cells. The funding will...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Delaqua Pharmaceuticals, Inc. aims to enhance the therapeutic use of hydrophobic drugs through a polymeric micelle approach to drug solubilization. The key objectives are to 1) improve the formulation of spherical micelles for enhanced stability and drug solubilization, 2) perform initial toxicity studies to establish the safety of the platform, and 3) demonstrate...
This SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $274,932 to Femtofluidics Incorporated to develop hardware that can rapidly and inexpensively synthesize DNA-encoded libraries (DELs) for accelerating drug discovery. The project aims to build a device that can perform combinatorial chemistry on nanoliter to picoliter droplets using an electronic substrate, without any moving or mechanical parts. This...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This $457,390 Project Grant award from the National Science Foundation's (NSF) Division of Materials Research aims to develop a new mRNA delivery system based on functional phosphoserine (PS) lipids. The award will support research to understand the targeted and immunomodulatory properties of these zwitterionic functional materials for mRNA delivery, with potential applications in gene therapy, protein-replacement therapy, and cancer immunotherapy. Key objectives include enhancing mRNA...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,445 to Endura Therapeutics Inc. aims to develop a next-generation sequencing platform for discovering small molecules that target RNA. The project seeks to demonstrate that small molecules binding to messenger RNA can modulate protein expression in cells and to create a high-throughput screening method to identify such molecules and their optimal RNA targets. The research...